LSD for PTSD

13 papers and 0 clinical trials exploring lsd as a treatment for ptsd.

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM-120 have reignited clinical development.

Full LSD profile
Indication354 million people suffering from PTSD globally.

PTSD

Posttraumatic stress disorder (PTSD) is a significant mental health challenge affecting over 354 million individuals globally. Psychedelics, particularly MDMA and psilocybin, are emerging as promising therapeutic options, offering new avenues for treatment through innovative psychotherapeutic interventions.

Full PTSD profile

Academic Research

13 papers
Open Accessindividual

A suite of engineered mice for interrogating psychedelic drug actions

The authors generated a suite of engineered Htr2a mouse lines—including an Htr2a‑EGFP‑CT‑IRES‑CreERT2 reporter, a humanised Htr2a line and a constitutive Htr2a‑Cre line—that enable independent visualisation of HTR2A receptors and HTR2A‑expressing cells and provide detailed anatomical and cell‑type maps. They validated the lines with psychedelic‑induced behavioural phenotypes and electrophysiology showing extracellular 5‑HT produces an HTR2A‑mediated increase in firing of genetically identified pyramidal neurons, consistent with plasma‑membrane localisation and utility for in vivo studies of psychedelic drug actions.

Published
Journal
Biorxiv
Authors
Bowyer, K., Chen, C., Chiu, Y-T., Deutch, A. Y., DiBerto, J. F., English, J., Herman, M. A., Huang, K. L., Hua, K., Kocak, D. D., Liu, B., Llorach, P., Mott, S. E., Niehaus, J., Roth, B. L., Scherrer, G., Schmitz, G. P., Sciaky, N., Walsh, J. J., Wang, W., Wetsel, W. C., Wu, Z.
Open Accessindividual

Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020

Analysis of 3,364 Global Drug Survey 2020 respondents who self-treated with LSD (n=1,996) or psilocybin mushrooms (n=1,368) found broadly favourable self-reported changes across 17 wellbeing and symptom items—largest effects on insight and mood—although 22.5% reported negative effects. Higher intensity, prior advice-seeking, use of psilocybin and treating PTSD predicted better averaged outcomes, while younger age, high intensity and LSD use predicted more negative effects, suggesting potential benefit but a higher adverse-event frequency than in clinical settings and informing safer community practice and clinical research.

Published
Journal
Journal of Psychopharmacology
Authors
Ferris, J. A., Kopra, E., Kuypers, K. P. C., Rucker, J., Winstock, A. R., Young, A. H.

Clinical Trials

0 trials

No clinical trials have been tagged with both LSD and PTSD yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all LSD papers Search all PTSD trials Full LSD profile Full PTSD profile